Dipeptidyl Peptidase IV in Inflammatory Bowel Diseases (DPP IV/CD26)

Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-9.10.1097/01.MIB.0000195385.19268.68Search in Google Scholar

Repiso A, Alcantara M, Munoz-Rosas C, Rodriguez-Merlo R, Perez-Grueso MJ, Carrobles JM, Carrobles JM, Martinez-Potenciano JL. Extraintestinal manifestations of Crohn's disease: prevalence and related factors. Rev Esp Enferm Dig 2006;98:510-7.10.4321/S1130-01082006000700004Search in Google Scholar

Sands BE, Grabert S. Epidemiology of inflammatory bowel disease and overview of pathogenesis. Med Health R I 2009;92:73-7.Search in Google Scholar

Hibi T. Molecular biological studies of the pathogenesis in inflammatory bowel disease. Intern Med 2003;42:285-7.10.2169/internalmedicine.42.285Search in Google Scholar

Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH.; Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the concept - what's in a name? Inflamm Bowel Dis 2008;14:850-7.Search in Google Scholar

Fatahzadeh M. Inflammatory bowel disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:e1-10.10.1016/j.tripleo.2009.07.035Search in Google Scholar

Baticic L, Detel D, Kucic N, Buljevic S, Pugel EP, Varljen J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem 2011;112:3322-33.10.1002/jcb.23261Search in Google Scholar

Hildebrandt M, Rose M, Rüter J, Salama A, Mönnikes H, Klapp BF. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol 2001;36:1067-72.10.1080/003655201750422675Search in Google Scholar

Varljen J, Mijandrušić Sinčić B, Batičić L, Varljen N, Detel D, Lekić A. Clinical relevance of the serum dipeptidyl peptidase IV (DPP IV/CD26) activity in adult patients with Crohn's disease and ulcerative colitis. Croat Chem Acta 2005;78:427-32.Search in Google Scholar

Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.10.1053/j.gastro.2004.01.063Search in Google Scholar

Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.10.1016/S0140-6736(07)60750-8Search in Google Scholar

Niv Y, Abuksis G, Fraser GM. Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 2000;95:693-8.10.1111/j.1572-0241.2000.01849.x10710059Search in Google Scholar

Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, Dotan I, Goh KL, Hibi T, Kozarek RA, Quigley EM, Reinisch W, Sands BE, Sollano JD, Steinhart AH, Steinwurz F, Vatn MH, Yamamoto-Furusho JK. IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 - Inflammatory bowel disease task force meeting. Inflamm Bowel Dis 2011;17:639-44.10.1002/ibd.2140920725944Search in Google Scholar

Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007;42:16-25.10.1007/s00535-006-1995-7278067417322989Search in Google Scholar

Sincić BM, Vucelić B, Persić M, Brncić N, Erzen DJ, Radaković B, Mićović V, Stimac D. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective population-based study. Scand J Gastroenterol 2006;41:437-44.10.1080/0036552050032009416635912Search in Google Scholar

Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2010;6:339-46.Search in Google Scholar

Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blakenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.10.1136/gut.39.5.69013833939014768Search in Google Scholar

Van Limbergen J, Russell RK, Nimmo ER, Satsangi J. The genetics of inflammatory bowel disease. Am J Gastroenterol 2007;102:2820-31.10.1111/j.1572-0241.2007.01527.x17894847Search in Google Scholar

Satsangi J, Morecroft J, Shah NB, Nimmo E. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003;17:3-18.10.1053/bega.2002.034912617879Search in Google Scholar

Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr Gastroenterol Rep 2002;4:481-9.10.1007/s11894-002-0024-012441038Search in Google Scholar

Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.10.1128/CMR.15.1.79-94.200211806111781268Search in Google Scholar

Noble C, Nimmo E, Gaya D, Russell RK, Satsangi J. Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol 2006;12:1991-9.10.3748/wjg.v12.i13.1991408767416610046Search in Google Scholar

Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.10.1038/nri113212876555Search in Google Scholar

Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Puig LP, Rousseau GC, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.10.1038/3507910711385576Search in Google Scholar

Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar J-P, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.10.1038/35079114Search in Google Scholar

Van Limbergen J, Russell RK, Nimmo ER, Ho GT, Arnott ID, Wilson DC, Satsangi J. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:338-55.10.1002/ibd.20096Search in Google Scholar

Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.10.1056/NEJMra020831Search in Google Scholar

Colletti T. IBD - recognition, diagnosis, therapeutics. JAAPA 2004;17:16-18, 21-14.Search in Google Scholar

Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:41-62.10.1016/S0889-8553(01)00004-8Search in Google Scholar

MacDonald TT. Gastrointestinal inflammation. Inflammatory bowel disease in knockout mice. Curr Biol 1994;4:261-3.10.1016/S0960-9822(00)00060-9Search in Google Scholar

Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Schölmerich J, Balfour Sartor R. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.10.1128/IAI.69.4.2277-2285.20019815611254584Search in Google Scholar

Cucchiara S, Iebba V, Conte MP, Schippa S. The microbiota in inflammatory bowel disease in different age groups. Dig Dis 2009;27:252-8.10.1159/00022855819786749Search in Google Scholar

Klement E, Lysy J, Hoshen M, Avitan M, Goldin E, Israeli E. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am J Gastroenterol 2008;103:1775-82.10.1111/j.1572-0241.2008.01905.x18557710Search in Google Scholar

Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn's disease and ulcerative colitis - an overview. J Physiol Pharmacol 2009;60(Suppl 6):61-71.Search in Google Scholar

Sanz Y, De Palma G. Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function. Int Rev Immunol 2009;28:397-413.10.3109/0883018090321561319954356Search in Google Scholar

Shah SA, Feller ER. Inflammatory bowel disease. Med Health R I 2009;92:72.Search in Google Scholar

Sonnenberg A. Occupational mortality of inflammatory bowel disease. Digestion 1990;46:10-8.10.1159/0002002732210092Search in Google Scholar

Kaplan GG, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, Wheeler AJ, Villeneuve PJ. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010;105:2412-9.10.1038/ajg.2010.252Search in Google Scholar

Henderson P, van Limbergen JE, Schwarze J, Wilson DC. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:382-95.10.1002/ibd.21379Search in Google Scholar

Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease - epidemiology and treatment. Aliment Pharmacol Ther 2009;30:99-112.10.1111/j.1365-2036.2009.04035.xSearch in Google Scholar

Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992;3:47-52.10.1097/00001648-199201000-00009Search in Google Scholar

Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010;68:280-9.10.1111/j.1753-4887.2010.00287.xSearch in Google Scholar

Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis 2008;14(Suppl 2):S14-15.10.1002/ibd.20555Search in Google Scholar

van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Dijkstra G. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009;15:1199-207.10.1002/ibd.20884Search in Google Scholar

Carbonnel F, Jantchou P, Monnet E, Cosnes J. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol Clin Biol 2009;33(Suppl 3):S145-57.10.1016/S0399-8320(09)73150-1Search in Google Scholar

Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004;18:481-96.10.1016/j.bpg.2003.12.00315157822Search in Google Scholar

Lakatos PL. Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 2009;27:215-25.10.1159/00022855319786744Search in Google Scholar

Peters CA, Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2006;66:424-9.10.1016/j.ijrobp.2006.05.027Search in Google Scholar

Broom OJ, Widjaya B, Troelsen J, Olsen J, Nielsen OH. Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 2009;158:272-80.10.1111/j.1365-2249.2009.04033.xSearch in Google Scholar

Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G175-84.10.1152/ajpgi.90454.2008Search in Google Scholar

Mentlein R. Cell-surface peptidases. Int Rev Cytol 2004;235:165-213.10.1016/S0074-7696(04)35004-7Search in Google Scholar

Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009;16:2943-51.10.2174/092986709788803114Search in Google Scholar

Van der Veken P, Haemers A, Augustyns K. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Topics Med Chem 2007;7:621-35.10.2174/156802607780091046Search in Google Scholar

Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001;1550:107-16.10.1016/S0167-4838(01)00278-3Search in Google Scholar

Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009;58:1723-47.10.1007/s00262-009-0728-119557413Search in Google Scholar

Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ, Gorrell MD. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999;29:1768-78.10.1002/hep.51029063110347120Search in Google Scholar

Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007;13:1736-41.10.1158/1078-0432.CCR-06-174617363526Search in Google Scholar

Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993;53:3327-35.Search in Google Scholar

Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Püschner H, Mauz M, Rettig WJ, Schnapp A. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000;20:1089-94.10.1128/MCB.20.3.1089-1094.20008522610629066Search in Google Scholar

Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000;267:6140-50.10.1046/j.1432-1327.2000.01617.x11012666Search in Google Scholar

Dubois V, Van Ginneken C, De Cock H, Lambeir AM, Van der Veken P, Augustyns K, Chen X, Scharpé S, De Meester I. Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem 2009;57:531-41.10.1369/jhc.2009.952739269040619188489Search in Google Scholar

Chen T, Smyth D, Abbott CA. Cd26. J Biolo Regul Homeost Agents 2004;18:47-54.Search in Google Scholar

Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005;108:277-92.10.1042/CS2004030215584901Search in Google Scholar

Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73.10.1078/0171-9335-0030212647932Search in Google Scholar

Liu Z, Christensson M, Forslöw A, De Meester I, Sundqvist KG. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009;183:3616-24.10.4049/jimmunol.080433619687096Search in Google Scholar

Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I, Scharpé S. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med 2009;47:248-52.Search in Google Scholar

Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966;7:197-201.10.1007/BF005778385959122Search in Google Scholar

Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993;177:1135-43.10.1084/jem.177.4.113521909628096237Search in Google Scholar

Lojda Z. Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry 1977;54:299-309.10.1007/BF00508273599045Search in Google Scholar

Kullertz G, Fischer G, Barth A. [Catalytic mechanism of dipeptidyl-peptidase IV, in German]. Acta Biol Med Ger 1978;37:559-67.Search in Google Scholar

Hanski C, Huhle T, Reutter W. Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler 1985;366:1169-76.10.1515/bchm3.1985.366.2.11692868739Search in Google Scholar

Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.10.1016/S0167-0115(99)00089-0Search in Google Scholar

Darmoul D, Lacasa M, Baricault L, Marguet D, Sapin C, Trotot P, Barbat A. Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem 1992;267:4824-33.10.1016/S0021-9258(18)42906-7Search in Google Scholar

Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang NH, Schlossman SF, Morimoto C. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci U S A 2001;98:12138-43.10.1073/pnas.211439098Search in Google Scholar

Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003;7:496-504.10.1016/S1367-5931(03)00084-XSearch in Google Scholar

Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993;82:1052-70.10.1182/blood.V82.4.1052.bloodjournal8241052Search in Google Scholar

Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-64.10.1046/j.1365-3083.2001.00984.xSearch in Google Scholar

Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994;15:180-4.10.1016/0167-5699(94)90316-6Search in Google Scholar

Muñoz E, Blazquez MV, Madueño JA, Rubio G, Peña J. CD26 induces T-cell proliferation by tyrosine protein phosphorylation. Immunology 1992;77:43-50.Search in Google Scholar

Bednarczyk JL, Carroll SM, Marin C, McIntyre BW. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 1991;46:206-18.10.1002/jcb.240460304Search in Google Scholar

Bühling F, Junker U, Reinhold D, Neubert K, Jäger L, Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995;45:47-51.10.1016/0165-2478(94)00230-OSearch in Google Scholar

Kahne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 1999;4:3-15.10.3892/ijmm.4.1.310373631Search in Google Scholar

Fleischer B, Sturm E, De Vries JE, Spits H. Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol 1988;141:1103-7.10.4049/jimmunol.141.4.1103Search in Google Scholar

Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992;79:3239-44.10.1182/blood.V79.12.3239.bloodjournal79123239Search in Google Scholar

Bühling F, Kunz D, Reinhold D, Ulmer AJ, Ernst M, Flad HD, Ansorge S. Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun 1994;13:270-9.Search in Google Scholar

Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994;40:331-8.10.1007/BF01246674Search in Google Scholar

Böhm SK, Gum JR, Jr., Erickson RH, Hicks JW, Kim YS. Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Biochem J 1995;311(Pt 3):835-43.10.1042/bj3110835Search in Google Scholar

Misumi Y, Hayashi Y, Arakawa F, Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta 1992;1131:333-6.10.1016/0167-4781(92)90036-YSearch in Google Scholar

Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth H-U, Brandstetter H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A 2003;100:5063-8.10.1073/pnas.0230620100Search in Google Scholar

Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25.10.1038/nsb882Search in Google Scholar

Bjelke JR, Christensen J, Branner S, Wagtmann N, Olsen C, Kanstrup AB, Rasmussen HB. Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. J Biol Chem 2004;279:34691-7.10.1074/jbc.M405400200Search in Google Scholar

Van Damme J, Struyf S, Wuyts A, Van Coillie E, Menten P, Schols D, Sozzani S, De Meester I, Proost P. The role of CD26/DPP IV in chemokine processing. Chem Immunol 1999;72:42-56.10.1159/000058725Search in Google Scholar

Hoffmann T, Faust J, Neubert K, Ansorge S. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett 1993;336:61-4.10.1016/0014-5793(93)81609-4Search in Google Scholar

Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpé S. Proline motifs in peptides and their biological processing. Faseb J 1995;9:736-44.10.1096/fasebj.9.9.7601338Search in Google Scholar

Wang XM, Yu DM, McCaughan GW, Gorrell MD. Extra-enzymatic roles of DPIV and FAP in cell adhesion and migration on collagen and fibronectin. Adv Exp Med Biol 2006;575:213-22.10.1007/0-387-32824-6_2316700525Search in Google Scholar

Martinez-Navio JM, Climent N, Pacheco R, Garcia F, Plana M, Nomdedeu M, Oliva H, Rovira C, Miralles L, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation. Immunology 2009;128:393-404.10.1111/j.1365-2567.2009.03121.x277068720067539Search in Google Scholar

Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, Tan VP, Yau TC, Poon RT, Wong BC. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010;6:603-15.10.1016/j.stem.2010.04.00120569697Search in Google Scholar

Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, Lendeckel U, Wolke C, Neubert K, Faust J, Fuchs P, Reinhold D, Thielitz A, Täger M. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009;47:253-61.10.1515/CCLM.2009.06319327105Search in Google Scholar

Reinhold D, Goihl A, Wrenger S, Reinhold A, Kühlmann UC, Faust J, Neubert K, Thielitz A, Brocke S, Täger M, Ansorge S, Bank U. Review: Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 2009;47:268-74.10.1515/CCLM.2009.06219676138Search in Google Scholar

De Meester I, Scharpé S, Lambeir AM. Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets. Clin Chem Lab Med 2009;47:245-7.10.1515/CCLM.2009.08519327103Search in Google Scholar

Schön E, Eichmann E, Grunow R, Jahn S, Kiessig ST, Volk HD, Ansorge S. Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochim Acta 1986;45:1523-8.Search in Google Scholar

Reinhold D, Kähne T, Steinbrecher A, Wrenger S, Neubert K, Ansorge S, Brocke S. The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem 2002;383:1133-8.10.1515/BC.2002.12312437097Search in Google Scholar

Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998;161:27-42.10.1111/j.1600-065X.1998.tb01569.xSearch in Google Scholar

Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A 2005;102:9583-8.10.1073/pnas.0501050102117224015983379Search in Google Scholar

Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 2007;7:253-73.10.2174/13895570778005985317346218Search in Google Scholar

Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:11-8.10.2174/156800804334003515032621Search in Google Scholar

Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7.10.1016/j.tips.2009.08.00319837468Search in Google Scholar

Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.10.1080/71360935412892317Search in Google Scholar

Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 2009;76(Suppl 5):S4-11.10.3949/ccjm.76.s5.0219952303Search in Google Scholar

Campbell RK, Neumiller JJ, White J, Sisson E, Kuhn C. Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist. J Am Pharm Assoc 2009;49(Suppl 1):S2.10.1331/JAPhA.2009.0953719801362Search in Google Scholar

Palalau AI, Tahrani AA, Piya MK, Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med 2009;121:70-100.10.3810/pgm.2009.11.207919940419Search in Google Scholar

Ahrén B. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diab Rep 2007;7:340-7.10.1007/s11892-007-0056-918173966Search in Google Scholar

Lupi R, Del Guerra S, D'Aleo V, Boggi U, Filipponi F, Marchetti P. The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets. Regul Pept 2010;165:129-32.10.1016/j.regpep.2010.04.00920472004Search in Google Scholar

Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF. A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci 2000;99:93-104.10.1042/CS19990368Search in Google Scholar

Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M. Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front Biosci 2008;13:3699-713.10.2741/296018508466Search in Google Scholar

Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, Imaoka A, Okada Y, Umesaki Y. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998;43:71-8.10.1136/gut.43.1.71Search in Google Scholar

Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS, Holst JJ. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000;141:4013-20.10.1210/endo.141.11.7752Search in Google Scholar

Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001;142:521-7.10.1210/endo.142.2.7983Search in Google Scholar

Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharmaceut Design 2006;12:1731-50.10.2174/138161206776873671Search in Google Scholar

Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999;276:G79-91.10.1152/ajpgi.1999.276.1.G79Search in Google Scholar

Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997;273:E77-84.10.1152/ajpendo.1997.273.1.E77Search in Google Scholar

Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotechnol 1997;15:673-7.10.1038/nbt0797-673Search in Google Scholar

Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003;33:1519-27.10.1002/eji.200323469Search in Google Scholar

Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.10.1016/0092-8674(93)80067-OSearch in Google Scholar

Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.10.1016/0092-8674(93)80068-PSearch in Google Scholar

Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.10.1016/0016-5085(95)90599-5Search in Google Scholar

Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Prot Immunol 2002;Chapter 15: Unit 15.19.Search in Google Scholar

Uhlig HH, Powrie F. Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. Eur J Immunol 2009;39:2021-6.10.1002/eji.200939602Search in Google Scholar

Grisham MB, Volkmer C, Tso P, Yamada T. Metabolism of trinitrobenzene sulfonic acid by the rat colon produces reactive oxygen species. Gastroenterology 1991;101:540-7.10.1016/0016-5085(91)90036-KSearch in Google Scholar

Ardite E, Sans M, Panés J, Romero FJ, Piqué JM, Fernández-Checa JC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest 2000;80:735-44.10.1038/labinvest.3780077Search in Google Scholar

Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-83.10.1016/j.addr.2007.07.003Search in Google Scholar

Hans W, Schölmerich J, Gross V, Falk W. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur J Gastroenterol Hepatol 2000;12:267-73.10.1097/00042737-200012030-00002Search in Google Scholar

Axelsson LG, Landström E, Bylund-Fellenius AC. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther 1998;12:925-34.10.1046/j.1365-2036.1998.00357.xSearch in Google Scholar

Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993;38:1722-34.10.1007/BF01303184Search in Google Scholar

Murthy S, Cooper HS, Yoshitake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999;13:251-60.10.1046/j.1365-2036.1999.00457.xSearch in Google Scholar

Ohkusa T. [Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and changes in intestinal microflora, in Japanese]. Nippon Shokakibyo Gakkai Zasshi 1985;82:1327-36.Search in Google Scholar

Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.10.1016/0016-5085(90)90290-HSearch in Google Scholar

Yamada M, Ohkusa T, Okayasu I. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut 1992;33:1521-27.10.1136/gut.33.11.1521Search in Google Scholar

Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000;62:240-8.10.1159/000007822Search in Google Scholar

Bailey RW, Bourne EJ. Intracellular glycosidases of dextran-producing bacteria. Nature 1961;191:277-8.10.1038/191277a0Search in Google Scholar

Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 2000;49:9-15.10.1538/expanim.49.9Search in Google Scholar

Venkatraman A, Ramakrishna BS, Pulimood AB, Patra S, Murthy S. Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scand J Gastroenterol 2000;35:1053-9.10.1080/003655200451171Search in Google Scholar

Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007;140:12-9.10.1016/j.jss.2006.07.050Search in Google Scholar

Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 1996;39:234-41.10.1136/gut.39.2.234Search in Google Scholar

Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A 2002;99:14338-43.10.1073/pnas.212290499Search in Google Scholar

Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.Search in Google Scholar

Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpe S, De Meester I. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 2001;507:327-30.10.1016/S0014-5793(01)02982-9Search in Google Scholar

Mentlein R, Dahms P, Grandt D, Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993;49:133-44.10.1016/0167-0115(93)90435-BSearch in Google Scholar

Bouras M, Huneau JF, Luengo C, Erlanson-Albertsson C, Tomé D. Metabolism of enterostatin in rat intestine, brain membranes, and serum: differential involvement of proline-specific peptidases. Peptides 1995;16:399-405.10.1016/0196-9781(94)00213-PSearch in Google Scholar

Nausch I, Mentlein R, Heymann E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol Chem Hoppe Seyler 1990;371:1113-8.10.1515/bchm3.1990.371.2.1113Search in Google Scholar

Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpé S, De Meester I. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000;267:5608-13.10.1046/j.1432-1327.2000.01634.xSearch in Google Scholar

Kato T, Nagatsu T, Fukasawa K, Harada M, Nagatsu I, Sakakibara S. Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl-aminopeptidase. Biochim Biophys Acta 1978;525:417-22.10.1016/0005-2744(78)90237-1Search in Google Scholar

Heymann E, Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett 1978;91:360-4.10.1016/0014-5793(78)81210-1Search in Google Scholar

Shane R, Wilk S, Bodnar RJ. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 1999;815:278-86.10.1016/S0006-8993(98)01121-4Search in Google Scholar

Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-72.10.1084/jem.186.11.186521991489382885Search in Google Scholar

Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpé S, Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998;273:7222-7.10.1074/jbc.273.13.72229516414Search in Google Scholar

Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, Honjo T, Nomoto A, Iwamoto A, Morimoto C, Nagai Y. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A 1998;95:6331-6.10.1073/pnas.95.11.6331276829600965Search in Google Scholar

Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augustyns K, Bal G, Haemers A, Lambeir AM, Scharpé S, Van Damme J, De Meester I. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988-93.10.1074/jbc.274.7.39889933589Search in Google Scholar

Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts JP, Detheux M, Parmentier M, De Meester I, Scharpé S, Van Damme J. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162:4903-9.10.4049/jimmunol.162.8.4903Search in Google Scholar

Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.10.1111/j.1432-1033.1993.tb17986.xSearch in Google Scholar

Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1992;1122:147-53.10.1016/0167-4838(92)90317-7Search in Google Scholar